Lilly's 'Triple-G' Obesity Drug Shows Strong Results in Alleviating Fatty Liver Disease.
Eli Lilly's experimental obesity drug, retatrutide, significantly reduced liver fat in a small clinical trial of 98 patients with nonalcoholic fatty liver disease. Patients on the highest dose experienced an 86% decrease in liver fat over 48 weeks, with 93% achieving resolution of the disease. The results support further studies of the treatment against the increasingly common condition that lacks approved treatments.